 |
|
Forecasting the Impact of a Clinical Practice Guideline for Perioperative  -Blockers to Reduce Cardiovascular Morbidity and Mortality
Michael Schmidt, BS;
Peter K. Lindenauer, MD, MSc;
Jan L. Fitzgerald, MS, RN;
Evan M. Benjamin, MD
Arch Intern Med. 2002;162:63-69.
Background  -Blockers reduce morbidity and mortality
when administered to high-risk patients undergoing major noncardiac surgery,
yet little is known about how often they are being prescribed. Clinical practice
guidelines are tools that can be used to speed the translation of research
into practice and may be one method to improve the use of -blockers.
Before implementing any guideline, it is important to forecast its potential
clinical and financial impact.
Methods We conducted a retrospective cohort study, using administrative and
medical record review data, of all adult patients undergoing major noncardiac
surgery at Baystate Medical Center, Springfield, Mass, during a 1-month period
in 1999. Patients with 2 or more cardiac risk factors or with documented coronary
artery disease were classified as high risk and were considered eligible for
treatment with a -blocker if they had no obvious contraindications to
its use. We estimated the potential clinical benefit of treating eligible
patients with a -blocker by extrapolating the treatment effect observed
in a previously reported randomized clinical trial.
Results Of 158 patients undergoing major noncardiac surgery, 67 (42.4%) seemed
to be ideal candidates for treatment with perioperative -blockers. Of
these 67 patients, 25 (37%) received a -blocker at some time perioperatively.
During the course of a year, we estimate that between 560 and 801 patients
who do not receive -blockers might benefit from treatment with these
medications. Full use of -blockers among eligible patients at our institution
could result in 62 to 89 fewer deaths each year at an overall cost of $33 661
to $40 210.
Conclusions There seems to be a large opportunity to improve the quality of care
of patients undergoing major noncardiac surgery by increasing the use of -blockers
in the perioperative period. A clinical practice guideline may be one method
to achieve these goals at little cost.
From the Department of Biostatistics and Epidemiology, University of
Massachusetts at Amherst (Mr Schmidt); the Department of Medicine, Tufts University
School of Medicine, Boston (Drs Lindenauer and Benjamin); and the Department
of Medicine (Drs Lindenauer and Benjamin) and the Division of Healthcare Quality
(Drs Lindenauer and Benjamin and Ms Fitzgerald), Baystate Medical Center,
Springfield, Mass.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(1):111.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery
Fleisher et al.
J Am Coll Cardiol 2007;50:e159-e242.
FULL TEXT
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)
Fleisher et al.
Circulation 2007;116:e418-e500.
FULL TEXT
Should the ACC/AHA guidelines be changed in patients undergoing vascular surgery?
Hoeks et al.
Eur Heart J 2005;26:2358-2360.
FULL TEXT
The effect of perioperative beta-blockers on patients undergoing noncardiac surgery - is the answer in?/L'effet des beta-blo-quants perioperatoires sur les patients de chirurgie non cardiaque - avons-nous la reponse ?
Devereaux et al.
Canadian J. Anesthesia 2004;51:749-755.
FULL TEXT
Perioperative use of beta-blockers remains low: experience of a single Canadian tertiary institution: [L'usage perioperatoire des beta-bloquants n'est pas frequent : l'experience d'un seul centre tertiaire canadien]
Rapchuk et al.
Canadian J. Anesthesia 2004;51:761-767.
ABSTRACT
| FULL TEXT
The Potential Preventability of Postoperative Myocardial Infarction: Underuse of Perioperative {beta}-Adrenergic Blockade
Lindenauer et al.
Arch Intern Med 2004;164:762-766.
ABSTRACT
| FULL TEXT
|
